Pneumokokna bolest i cijepljenje protiv pneumokoka

Slides:

Advertisements

Similar presentations

Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.

Advertisements

Hot Topics in Pediatric ID Robert J. Leggiadro, MD Chairman Department of Pediatrics Lincoln Medical Center Professor of Clinical Pediatrics Weill Medical.

Carlos G. Grijalva, MD MPH Department of Preventive Medicine Vanderbilt University School of Medicine Nashville, Tennessee.

Impact of the Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease (IPD) in Ireland Data source: National Pneumococcal.

Indication for Otitis Media FDA Vaccine and Related Biologicals Advisory Committee Meeting May 21, 2002 Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria.

By Ahmed Khaled Vaccine team Pfizer KSA

Epidemiology of Pneumococcal Disease in the U.S. in the Conjugate Vaccine Era Food and Drug Administration Center for Biologics Evaluation and Research.

Evaluation of the resistance of bacterial pathogens of synopulmonary infections in children L.Chernyshova F.Lapiy National Medical Academy of Postgraduate.

Created byInformation Design A Mathematical Model for the Impact of the Conjugate Vaccine on S. pneumoniae Vaccine and Non-vaccine serotypes Robertino.

Modeling of the effect of pneumococcal conjugate vaccination on carriage and transmission of Streptococcus pneumoniae in Kenyan children John Ojal KEMRI-Wellcome.

1 Vaccines and Related Biological Products Advisory Committee Meeting November 18, 2009 Questions for the Committee Prevnar 13 Pneumococcal 13-valent Conjugate.

1 Zithromax  (Azithromycin) Oral Suspension Single-Dose & 3-day Treatment of Acute Otitis Media Anti-Infective Drugs Advisory Committee November 7, 2001.

Pneumococcal Vaccine Use Around the World: Successes and Challenges Adam L. Cohen, MD MPH Respiratory Diseases Branch, Division of Bacterial Diseases Centers.

1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.

C. Jillian Tsai, Ph.D. Department of Preventive Medicine

Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010 Koh Cheng Thoon, Chia Yin Chong,

Acute Mastoiditis in the Pneumococcal Conjugate Vaccines Era

Vaccines and Related Biological Products Advisory Committee Meeting

* LABORATORY-BASED SURVEILLANCE OF S. PNEUMONIAE INVASIVE DISEASE (IPD) IN CHILDREN: SEROTYPE DISTRIBUTION AND ESTIMATION OF VACCINES COVERAGE B. V. M.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 5 Sample format for results of Streptococcus pneumoniae isolate testing in a laboratory that routinely performs only oxacillin disk tests for penicillin.

Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation.

بسم الله الرحمن الرحیم.

Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study Dr.

Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period J. Liñares, C. Ardanuy, R. Pallares, A.

The State of Pneumococcal Disease Prevention

Pneumococcal Disease Prevention in Children: Issues in the Era of PCVs

Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the.

Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era S. Nunes,

Necrotizing pneumonia caused by nanC-carrying serotypes is associated with pneumococcal haemolytic uraemic syndrome in children R.-P. Janapatla, M.-H.

Assessment of Streptococcus pneumoniae pilus islet-1 prevalence in carried and transmitted isolates from mother–infant pairs on the Thailand–Burma border

When less is more: how many doses of PCV are enough?

The laws of acute otitis media

Clinical Microbiology and Infection

Pneumococcal conjugate vaccines: overview of a decade from Kuwait

Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine E. Calbo, Á. Díaz, E.

Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era S. Nunes,

Prevalence of pilus-encoding islets among acute otitis media Streptococcus pneumoniae isolates from Israel M. Moschioni, G. De Angelis, S. Melchiorre,

The role of vaccination in preventing pneumococcal disease in adults

Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis Dr Tinevimbo.

Prevalence of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern.

Addressing Pneumococcal Disease in Latino Communities

Carriage of resistant pneumococci by children in southern Israel and impact of conjugate vaccines on carriage Ron Dagan, Drora Fraser, Noga Givon, Pablo.

Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Stefanie Desmet, Jan Verhaegen, Marc Van Ranst,

Daniel M. Musher, MD Mayo Clinic Proceedings

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

Development and testing of Streptococcus pneumoniae conjugate vaccines

Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae.

Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic.

Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens* M. Kanellopoulou, A. Makri,

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults* P. Durando, S.N. Faust,

Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort.

Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989–2008) C. Esteva, L. Selva, M.F.

Respiratory viruses, such as 2009 H1N1 influenza virus, could trigger temporal trends in serotypes causing pneumococcal disease C. Launes, J.-J. García-García,

T.M. File Clinical Microbiology and Infection

Role of communicable disease control measures in affecting the spread of resistant pneumococci: the Swedish model Karl Ekdahl, Otto Cars Clinical Microbiology.

Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media;

Changes in Streptococcus pneumoniae serotypes causing invasive disease with non- universal vaccination coverage of the seven-valent conjugate vaccine

F. Schaumburg, B. Biallas, E. Ngoune Feugap, A. S. Alabi, B

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational.

Clinical Microbiology and Infection

Sensitivity to immunity parameters.

One-way sensitivity analysis.

Data source: Irish Pneumococcal Reference Laboratory

Outline Background Licensed pneumococcal conjugate vaccines

National Immunization Conference

Serotype 10A in Invasive Pneumococcal Disease (IPD) Surveillance in New Jersey, April – September 2009 Samantha Pitts, MD, MPH CDC/CSTE Applied Epidemiology.

Invasive Pneumococcal Disease Serotypes After the Introduction of Pneumococcal Seven-Valent Conjugate Vaccine Arizona, Susan Goodykoontz, Daniel.

Percentage of pneumococcal isolates within each vaccine group for 2001 and Percentage of pneumococcal isolates within each vaccine group for 2001.

Presentation transcript:

Pneumokokna bolest i cijepljenje protiv pneumokoka Goran Tešović Klinika za infektivne bolesti „Dr. Fran Mihaljević” Medicinski fakultet Sveučilišta u Zagrebu Simpozij „Bolesti koje se sprječavaju cijepljenjem”, Zagreb, 25. svibnja 2018. g.

Nazofarinks – najznačajnija biološka niša, početak bolesti, mjesto djelovanja CV…

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Nazofarinks – najznačajnija biološka niša, početak bolesti, mjesto djelovanja CV… Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa!

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Različiti kapsularni tipovi: različito dugo perzistiraju na sluznici; imaju različit invazijski potencijal; uzrokuju različite kliničke sindrome;

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Različiti kapsularni tipovi: različito dugo perzistiraju na sluznici; imaju različit invazijski potencijal; uzrokuju različite kliničke sindrome;

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Sleeman KL, Griffiths D, Shackley F, et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis. 2006 Sep 1;194:682-8.

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Različiti kapsularni tipovi: različito dugo perzistiraju na sluznici; imaju različit invazijski potencijal; uzrokuju različite kliničke sindrome;

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Sá-Leão R, Pinto F, Aguiar S, et al. Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. J Clin Microbiol. 2011;49:1369-75.

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Različiti kapsularni tipovi: različito dugo perzistiraju na sluznici; imaju različit invazijski potencijal; uzrokuju različite kliničke sindrome;

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Rodgers GL, Arguedas A, Cohen R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 2009;27:3802-10.

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Rodgers GL, Arguedas A, Cohen R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 2009;27:3802-10.

Ključna uloga polisaharidne kapsule – „kapsularnog” serotipa! Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci. 2013;28:4-15.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… MMWR 2008;57(6):144-8.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Lancet 2007;369:1179-86.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Pediatrics 2008;121:253-60.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… J Infect Dis 2007;196:1346-54.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine. Kaplan, Sheldon; Barson, William; Lin, Philana; Romero, Jose; Bradley, John; Tan, Tina; Hoffman, Jill; Givner, Laurence; Mason, Edward Pediatric Infectious Disease Journal. 32(3):203-207, March 2013. DOI: 10.1097/INF.0b013e318275614b

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Angoulvant F, et al. Clin Infect Dis. 2014;58(7):918-924.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Arrows: 1. PCV7 in private market, 2. PCV7 introduced to the Israeli NIP, 3. PCV13 introduced to the Israeli NIP, 4. >70% of children 7-11 months received ≥2 doses of PCV13. Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near elimination of otitis media caused by the PCV13 serotypes in Southern Israel shortly after sequential introduction of PCV7/PCV13. Clin Infect Dis. 2014 Aug 25. pii: ciu683.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… THL Report – Infectious Diseases in Finland 2015

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Best et al, Vaccine, 34:3840–3847, 2016

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… IPD cases/100,000 Regev-Yochay, Dagan et al, Vaccine 2017:35:2449-2456.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest…

Engleska i Wales (<5 godina) PCV13 2+1 *nije statistički značajno Waight PA, et al. Lancet Infect Dis. Published online 20 March 2015.

Moore MR, et al. Lancet Infect Dis. 2015;15(3):301-309. SAD (<5 godina) PCV13 3+1 PCV7 2000 PCV13 2010 31% redukcija (vs 2007–2010) Moore MR, et al. Lancet Infect Dis. 2015;15(3):301-309.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Broj sojeva Butić I, Tešović G: Neobjavljeni podaci, 2017.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Broj sojeva Butić I, Tešović G: Neobjavljeni podaci, 2017.

Koje su direktne posljedice PCV na pneumokokno kliconoštvo, bolest… Broj sojeva Butić I, Tešović G: Neobjavljeni podaci, 2017.

Zaključci PCV značajno utječe na epidemiologiju neinvazivnih i invazivnih oblika pneumokokne bolesti. PCV potiče zamjenu serotipova („novi” serotipovi popunjavaju „nišu”. Serotipovi (pa tako i zamjenski) značajno se razlikuju u invazijskom potencijalu, antimikrobnoj osjetljivosti… Poznavanje lokalne seroepidemiologije značajno je za donošenje odluke o tome koje je PCV optimalan izbor za NIP.